BioPoint Inc

BioPoint Inc. is a US-based Life Sciences consulting firm focused in the areas of Drug Safety.

is a US based life sciences consulting organization focused in the areas of Drug Safety, Health Economic

09/04/2026

Biotech is gaining momentum as M&A, venture funding and IPO activity rebound, setting a positive outlook for the rest of 2026. https://www.biospace.com/business/biotech-is-back-with-h1-progress-smoothing-glide-path-through-end-of-year-truist

With M&A rising, venture capital returning and policy risks easing, biotech is on a positive trajectory following a prolonged post-pandemic slump, Truist Securities declared after a survey of sector leaders.

09/03/2026

Revolution Medicines’ Rasonque showed promising results in RAS-mutant lung cancer, supporting its ongoing Phase 3 trial. https://www.biospace.com/drug-development/revmeds-newly-approved-rasonque-could-hold-up-in-non-small-cell-lung-cancer

The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall response rate and overall survival of 16 months.

09/02/2026

Biotech funding announcements can help job seekers identify companies likely to hire before positions are publicly posted. https://www.biospace.com/career-advice/follow-the-money-how-funding-announcements-can-help-identify-jobs-before-theyre-posted

Funding announcements can signal future hiring activity, giving biotech professionals a chance to build relationships before positions are posted. Industry experts share how to identify the funding events, milestones and company indicators most likely to lead to new jobs.

09/01/2026

GSK is advancing its mRNA flu vaccine to Phase 3 after showing stronger immune responses than existing vaccines in a mid-stage trial. https://www.biospace.com/drug-development/gsk-to-launch-phase-3-trial-for-mrna-based-flu-vaccine-amid-resurgence-for-the-modality

GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA's recent approval for Moderna’s mRNA flu vaccine.

08/31/2026

Arrowhead’s Redemplo showed strong triglyceride reductions in Phase 3, but analysts remain divided over its competitive edge against Ionis’ Tryngolza. https://www.biospace.com/drug-development/arrowheads-new-redemplo-findings-in-severe-hypertriglyceridemia-have-analysts-split

Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.

08/28/2026

Lilly’s Mounjaro won FDA approval to reduce cardiovascular risk in adults with type 2 diabetes. https://www.biospace.com/fda/lilly-joins-novo-in-cardiovascular-space-after-fda-nod-for-glp-1-gip-agonist-mounjaro

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.

08/27/2026

Revolution Medicines could emerge as a major oncology player following FDA approval of Rasonque for pancreatic cancer. https://www.biospace.com/business/revmed-could-become-next-oncology-titan-with-rasonque-nod

A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.

08/26/2026

Revolution Medicines received FDA approval for Rasonque, a groundbreaking pancreatic cancer drug, 6.5 months ahead of schedule. https://www.biospace.com/drug-development/revmed-receives-early-fda-approval-for-groundbreaking-pancreatic-cancer-drug

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.

08/25/2026

Bausch + Lomb is advancing its dry eye therapy to Phase 3 despite missing its primary Phase 2 endpoint, citing promising earlier results. https://www.biospace.com/drug-development/bausch-lomb-advances-dry-eye-disease-drug-to-phase-3-despite-mid-stage-fail

While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.

08/24/2026

The FDA extended its review of Capricor’s Duchenne therapy by three months to evaluate additional data and a refined indication. https://www.biospace.com/fda/capricors-duchenne-therapy-has-new-life-after-fda-grants-3-month-extension

The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication. The new target action date for the therapy is November 22.

Address

13 Centennial Drive Ste. 1
Peabody, MA
01960

Website

http://www.biopointinc.com/

Alerts

Be the first to know and let us send you an email when BioPoint Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BioPoint Inc:

Want your practice to be the top-listed Clinic in Peabody?